New landmark review paper highlights performance benefits of etafilcon A material.¹

Thirty years of ‘quiet eye’ with etafilcon A contact lenses

Nathan Efron⁴, Noel A. Brennan⁵, Robin L. Chalmers⁶, Lyndon Jones⁷, Charis Lau⁸, Philip B. Morgan⁹, Jason J. Nichols¹, Loretta B. Szczotka-Flynn⁹, Mark D.Willcox⁹

¹Based on in-vitro data; clinical studies have not been done directly linking differences in lysozyme profile with specific clinical benefits.

This observational/surveillance registry relied on patient reports of symptomatic adverse events that led them to seek clinical care. These results should be considered in conjunction with other clinical results on the safety and efficacy of daily disposable etafilcon A contact lenses, which also generally show low rates of such events. Although no symptomatic infiltrative events were reported in this study, such events can occur with daily disposable lenses, including 1-DAY ACUVUE® MOIST, as noted in the product labeling.

¹¹JJV data on file 2018. Source: Euromonitor International; based on research conducted in August 2018; “world” and “globally” represent markets accounting for 80.8% of total daily disposable contact lenses in 2017 (retail sales). Claim effective starting September 24, 2018.

¹²FOR MORE INFORMATION including a link to the actual publication: https://bit.ly/33y5kmn

¹ Led by Professor Nathan Efron, a team of eminent researchers have recently come together to summarise the extensive body of research, conducted by themselves and others, that sets out the considerable performance benefits of etafilcon A contact lenses (the material behind 1-DAY ACUVUE® MOIST) conducted over the last three decades. Key findings in this review are:

Low inflammatory response and infection risk profile during daily wear.
This may be related to the low modulus and the naturally protective anti-microbial non-denatured lysozyme absorbed into the lens from the tear fluid (with in-vitro testing.*)

Equivalent levels of corneal oxygenation compared to silicone hydrogel materials are maintained during daily wear of low to medium powered etafilcon A lenses.

Looking at material type
Silicone hydrogel lenses in general do not appear to show differences in dryness and discomfort compared to hydrogel materials.

Etafilcon A remains the most widely used hydrogel material today and remains an important alternative for daily wear in modern contact lens practice.¹

¹Based on in-vitro data; clinical studies have not been done directly linking differences in lysozyme profile with specific clinical benefits.

¹¹This observational/surveillance registry relied on patient reports of symptomatic adverse events that led them to seek clinical care. These results should be considered in conjunction with other clinical results on the safety and efficacy of daily disposable etafilcon A contact lenses, which also generally show low rates of such events. Although no symptomatic infiltrative events were reported in this study, such events can occur with daily disposable lenses, including 1-DAY ACUVUE® MOIST, as noted in the product labeling.

¹¹¹JJV data on file 2018. Source: Euromonitor International; based on research conducted in August 2018; “world” and “globally” represent markets accounting for 80.8% of total daily disposable contact lenses in 2017 (retail sales). Claim effective starting September 24, 2018.

¹²FOR MORE INFORMATION including a link to the actual publication: https://bit.ly/33y5kmn

164 articles analyzed


IMPORTANT SAFETY INFORMATION: ACUVUE® Contact Lenses are indicated for vision correction. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Lenses should not be prescribed if patients have any eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. Consult the package insert for complete information. Complete information is also available from Johnson & Johnson Vision Care division of Johnson & Johnson Inc., by calling 1-800-287-0098 or by visiting jnjvisionpro.ca.

© Johnson & Johnson Vision Care division of Johnson & Johnson Inc. 2020 PP20201DAV/M5187 AS-10-20-04-CE